TY - JOUR
T1 - Whiplash injury successfully treated with prolotherapy
T2 - A case report with long-term follow up
AU - Stogicza, Agnes R.
AU - Guo, Michael Yu Feng
AU - Rabago, David
N1 - Publisher Copyright:
© 2020
PY - 2020/9
Y1 - 2020/9
N2 - Background: Chronic whiplash-associated disorder (WAD) can develop after flexion/extension injuries and may be refractory to standard-of-care therapies. Aim: To present successful treatment of severe, longstanding, treatment resistant WAD with prolotherapy. Materials & methods: Four, monthly sessions of fluoroscopically guided prolotherapy with phenol-glycerin-glucose. Electronic data on pain (visual analog score), disability (Oswestry Disability Index), pain interference, depression, anxiety, sleep and quality of life were collected with University of Washington's (WA, USA) online tool for a total of 21 months. This study conforms to the Case Report Guidelines (CARE). Results: Significant improvement was achieved and maintained through 18 months after treatment in all assessed pain and functional measures. Conclusion: Regenerative medicine, including prolotherapy may be an appropriate treatment option for carefully selected patients with WAD.
AB - Background: Chronic whiplash-associated disorder (WAD) can develop after flexion/extension injuries and may be refractory to standard-of-care therapies. Aim: To present successful treatment of severe, longstanding, treatment resistant WAD with prolotherapy. Materials & methods: Four, monthly sessions of fluoroscopically guided prolotherapy with phenol-glycerin-glucose. Electronic data on pain (visual analog score), disability (Oswestry Disability Index), pain interference, depression, anxiety, sleep and quality of life were collected with University of Washington's (WA, USA) online tool for a total of 21 months. This study conforms to the Case Report Guidelines (CARE). Results: Significant improvement was achieved and maintained through 18 months after treatment in all assessed pain and functional measures. Conclusion: Regenerative medicine, including prolotherapy may be an appropriate treatment option for carefully selected patients with WAD.
UR - http://www.scopus.com/inward/record.url?scp=85097889201&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85097889201&partnerID=8YFLogxK
U2 - 10.2217/rme-2020-0063
DO - 10.2217/rme-2020-0063
M3 - Article
C2 - 33259262
AN - SCOPUS:85097889201
SN - 1746-0751
VL - 15
SP - 2075
EP - 2084
JO - Regenerative Medicine
JF - Regenerative Medicine
IS - 9
ER -